Attached files

file filename
10-K/A - AMENDMENT NO. 1 TO FORM 10-K - LIGAND PHARMACEUTICALS INCd340139d10ka.htm
EX-32.1 - CERTIFICATION - LIGAND PHARMACEUTICALS INCd340139dex321.htm
EX-31.1 - CERTIFICATION - LIGAND PHARMACEUTICALS INCd340139dex311.htm
EX-31.2 - CERTIFICATION - LIGAND PHARMACEUTICALS INCd340139dex312.htm
EX-23.1 - CONSENT OF GRANT THORNTON LLP - LIGAND PHARMACEUTICALS INCd340139dex231.htm
EX-10.133 - LICENSE AND SUPPLY AGREEMENT - LIGAND PHARMACEUTICALS INCd340139dex10133.htm
EX-10.131 - LICENSE AGREEMENT - LIGAND PHARMACEUTICALS INCd340139dex10131.htm

Exhibit 32.2

CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K, as amended by the accompanying amendment No. 1 on Form 10-K/A of Ligand Pharmaceuticals Incorporated (the “Company”) for the year ended December 31, 2011, I, John P. Sharp, Vice President, Finance and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

(1) such Annual Report on Form 10-K, as amended by the accompanying amendment No. 1 on Form 10-K/A for the year ended December 31, 2011, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in such Annual Report on Form 10-K, as amended by the accompanying amendment No. 1 on Form 10-K/A for the year ended December 31, 2011, fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished solely to accompany such Annual Report on Form 10-K, as amended by the accompanying amendment No. 1 on Form 10-K/A for the year ended December 31, 2011, pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Date: May 16, 2012

 

/s/ John P. Sharp

  John P. Sharp
 

Vice President, Finance and Chief Financial Officer

(Principal Financial Officer)